Edgewise Therapeutics, Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Edgewise Therapeutics, Inc.
- Company name
- Edgewise Therapeutics, Inc.
- Organisation type
- Industry
- Registered legal name
- Edgewise Therapeutics, Inc.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- Headquarters country
- United States
- Publicly traded (proxy)
- Yes
- Listing at source
- Listed
- SEC filer number (CIK)
- 0001710072
Related records
Trials (19)
- A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
- A Study of EDG-15400 in Healthy Adults
- A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
- A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
- A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
- A Study of EDG-7500 in Healthy Adults
- A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults
- A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling
- A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
- A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults
- A Study to Evaluate EDG-7500 in People With Renal Impairment
- A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers
- A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500
- Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
- Defining Endpoints in Becker Muscular Dystrophy
- Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases
- Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
- Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
- Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy